CN113912717B - Egfl6特异性单克隆抗体及其使用方法 - Google Patents

Egfl6特异性单克隆抗体及其使用方法 Download PDF

Info

Publication number
CN113912717B
CN113912717B CN202110985801.8A CN202110985801A CN113912717B CN 113912717 B CN113912717 B CN 113912717B CN 202110985801 A CN202110985801 A CN 202110985801A CN 113912717 B CN113912717 B CN 113912717B
Authority
CN
China
Prior art keywords
antibody
seq
domain
ser
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110985801.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113912717A (zh
Inventor
N·张
Z·安
A·K·苏德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Priority to CN202110985801.8A priority Critical patent/CN113912717B/zh
Publication of CN113912717A publication Critical patent/CN113912717A/zh
Application granted granted Critical
Publication of CN113912717B publication Critical patent/CN113912717B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
CN202110985801.8A 2016-02-05 2017-02-06 Egfl6特异性单克隆抗体及其使用方法 Active CN113912717B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110985801.8A CN113912717B (zh) 2016-02-05 2017-02-06 Egfl6特异性单克隆抗体及其使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662291987P 2016-02-05 2016-02-05
US62/291,987 2016-02-05
CN202110985801.8A CN113912717B (zh) 2016-02-05 2017-02-06 Egfl6特异性单克隆抗体及其使用方法
CN201780015519.9A CN109562163B (zh) 2016-02-05 2017-02-06 Egfl6特异性单克隆抗体及其使用方法
PCT/US2017/016659 WO2017136807A1 (en) 2016-02-05 2017-02-06 Egfl6 specific monoclonal antibodies and methods of their use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780015519.9A Division CN109562163B (zh) 2016-02-05 2017-02-06 Egfl6特异性单克隆抗体及其使用方法

Publications (2)

Publication Number Publication Date
CN113912717A CN113912717A (zh) 2022-01-11
CN113912717B true CN113912717B (zh) 2024-05-03

Family

ID=59501106

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110985801.8A Active CN113912717B (zh) 2016-02-05 2017-02-06 Egfl6特异性单克隆抗体及其使用方法
CN201780015519.9A Active CN109562163B (zh) 2016-02-05 2017-02-06 Egfl6特异性单克隆抗体及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780015519.9A Active CN109562163B (zh) 2016-02-05 2017-02-06 Egfl6特异性单克隆抗体及其使用方法

Country Status (12)

Country Link
US (3) US10875912B2 (https=)
EP (1) EP3411070A4 (https=)
JP (4) JP2019512210A (https=)
KR (1) KR20180105704A (https=)
CN (2) CN113912717B (https=)
AU (2) AU2017214685B2 (https=)
BR (1) BR112018015826A2 (https=)
CA (2) CA3298267A1 (https=)
MX (1) MX2018009499A (https=)
SG (1) SG11201806622PA (https=)
WO (1) WO2017136807A1 (https=)
ZA (1) ZA201805051B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113912717B (zh) * 2016-02-05 2024-05-03 得克萨斯大学体系董事会 Egfl6特异性单克隆抗体及其使用方法
TWI696632B (zh) * 2017-10-01 2020-06-21 臺北醫學大學 抗-類egf結構域多重6(egfl6)抗體及其於癌症診斷及治療中之應用
EP3902830A1 (en) * 2018-12-30 2021-11-03 F. Hoffmann-La Roche AG Anti-rabbit cd19 antibodies and methods of use
CN110951733A (zh) * 2019-11-27 2020-04-03 山西医科大学 一种靶向抑制食管癌EGFL6基因表达的siRNA及构建的表达载体和应用
CN116381251B (zh) * 2023-03-13 2024-06-25 柏定生物工程(北京)有限公司 一种肿瘤标志物诊断试剂盒及其诊断方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014150720A1 (en) * 2013-03-15 2014-09-25 The Regents Of The University Of Michigan Compositions and methods relating to inhibiting cancer cell growth and/or proliferation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174957T5 (es) * 1994-07-29 2006-12-16 Innogenetics N.V. Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico.
US20030036508A1 (en) 1997-11-22 2003-02-20 John Ford EGF motif protein, EGFL6 materials and methods
AU2002213259A1 (en) 2000-10-13 2002-04-22 Hyseq, Inc. Egf motif protein, egfl6 materials and methods
US20100119550A1 (en) * 2005-11-24 2010-05-13 Yasuyuki Gomi Recombinant multivalent vaccine
AR059851A1 (es) * 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
BRPI0914251B1 (pt) * 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
US8501197B2 (en) * 2010-04-30 2013-08-06 The Research Foundation for The State of New York Compositions and methods for stimulating immune response against Moraxella catarrhalis
EP2758434A2 (en) * 2011-09-23 2014-07-30 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Anti-tumor necrosis factor-alpha agents and uses thereof
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CN113912717B (zh) * 2016-02-05 2024-05-03 得克萨斯大学体系董事会 Egfl6特异性单克隆抗体及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014150720A1 (en) * 2013-03-15 2014-09-25 The Regents Of The University Of Michigan Compositions and methods relating to inhibiting cancer cell growth and/or proliferation

Also Published As

Publication number Publication date
US20210130450A1 (en) 2021-05-06
RU2018131611A3 (https=) 2020-05-19
AU2017214685A1 (en) 2018-08-09
BR112018015826A2 (pt) 2019-01-02
CA3012696A1 (en) 2017-08-10
JP2022008309A (ja) 2022-01-13
CN109562163B (zh) 2022-04-08
CN113912717A (zh) 2022-01-11
SG11201806622PA (en) 2018-09-27
MX2018009499A (es) 2019-05-06
WO2017136807A1 (en) 2017-08-10
JP7358426B2 (ja) 2023-10-10
JP2019512210A (ja) 2019-05-16
US20190031751A1 (en) 2019-01-31
EP3411070A1 (en) 2018-12-12
CN109562163A (zh) 2019-04-02
ZA201805051B (en) 2023-05-31
AU2017214685B2 (en) 2024-03-07
AU2024203614A1 (en) 2024-06-20
NZ784700A (en) 2025-05-02
US20250145702A1 (en) 2025-05-08
US12152071B2 (en) 2024-11-26
EP3411070A4 (en) 2019-11-27
JP2024164139A (ja) 2024-11-26
RU2018131611A (ru) 2020-03-05
JP2023130411A (ja) 2023-09-20
NZ744609A (en) 2025-03-28
KR20180105704A (ko) 2018-09-28
CA3298267A1 (en) 2026-03-02
US10875912B2 (en) 2020-12-29

Similar Documents

Publication Publication Date Title
US11174320B2 (en) HER3 specific monoclonal antibodies for diagnostic and therapeutic use
JP7358426B2 (ja) Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法
EP3191525A1 (en) Blocking monoclonal antibodies to agr2 and its receptor c4.4a
US20250270312A1 (en) Monoclonal antibodies against endotrophin and the use thereof
US10385129B2 (en) JAM-C antibodies and methods for treatment of cancer
US10729781B2 (en) LGR4 specific monoclonal antibodies and methods of their use
RU2779902C2 (ru) Egfl6-специфические моноклональные антитела и способы их применения
WO2025090760A1 (en) Antibodies specific to scube3 and methods of use
HK1213584B (en) Jam-c antibodies and methods for treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant